Onco-Targets – Making loss of SFRP tumour suppressor function druggable
The invention discloses molecules, which are activated,
when function of Secreted Fizzled Related Protein 1 (SFRP1) is lost. SFRP1 is known to have tumour suppressor function and its loss is associated to tumour progression and poor survival. Access to the signalling pathways regulated by SFRP1 leads to novel targets for cancer therapy and diagnosis. Such druggable targets open the route to screening of small molecules and design of monoclonal antibodies, thereby enabling the development of innovative oncological treatments as well as new diagnostic markers.
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 10
Contact
Dipl.-Ing. Alfred Schillert
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Future AR/VR controllers could be the palm of your hand
Carnegie Mellon University’s EgoTouch creates simple interfaces for virtual and augmented reality. The new generation of augmented and virtual reality controllers may not just fit in the palm of your…
‘Game changer’ in lithium extraction
Rice researchers develop novel electrochemical reactor. A team of Rice University researchers led by Lisa Biswal and Haotian Wang has developed an innovative electrochemical reactor to extract lithium from natural…
The blue-green sustainable proteins of seaweed
… may soon be on your plate. The protein in sea lettuce, a type of seaweed, is a promising complement to both meat and other current alternative protein sources. Seaweed…